Skip to main content
Top
Published in: The European Journal of Health Economics 5/2011

Open Access 01-10-2011 | Original Paper

Largely ignored: the impact of the threshold value for a QALY on the importance of a transferability factor

Authors: Pepijn Vemer, Maureen P. M. H. Rutten-van Mölken

Published in: The European Journal of Health Economics | Issue 5/2011

Login to get access

Abstract

Recently, several checklists systematically assessed factors that affect the transferability of cost-effectiveness (CE) studies between jurisdictions. The role of the threshold value for a QALY has been given little consideration in these checklists, even though the importance of a factor as a cause of between country differences in CE depends on this threshold. In this paper, we study the impact of the willingness-to-pay (WTP) per QALY on the importance of transferability factors in the case of smoking cessation support (SCS). We investigated, for several values of the WTP, how differences between six countries affect the incremental net monetary benefit (INMB) of SCS. The investigated factors were demography, smoking prevalence, mortality, epidemiology and costs of smoking-related diseases, resource use and unit costs of SCS, utility weights and discount rates. We found that when the WTP decreased, factors that mainly affect health outcomes became less important and factors that mainly effect costs became more important. With a WTP below €1,000, the factors most responsible for between country differences in INMB were resource use and unit costs of SCS and the costs of smoking-related diseases. Utility values had little impact. At a threshold above €10,000, between country differences were primarily due to different discount rates, utility weights and epidemiology of smoking-related diseases. Costs of smoking-related diseases had little impact. At all thresholds, demography had little impact. We concluded that, when judging the transferability of a CE study, we should consider the between country differences in WTP threshold values.
Appendix
Available only for authorised users
Literature
1.
go back to reference Drummond, M., Barbieri, M., Cook, J., Glick, H., Lis, J., Malik, F., et al.: Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report. Value Health 12, 409–418 (2009)PubMedCrossRef Drummond, M., Barbieri, M., Cook, J., Glick, H., Lis, J., Malik, F., et al.: Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report. Value Health 12, 409–418 (2009)PubMedCrossRef
2.
go back to reference Boulenger, S., Nixon, J., Drummond, M.F., Ulmann, P., Rice, S., de Pouvourville, G.: Can economic evaluations be made more transferable? Eur. J. Health Econ. 6, 334–346 (2005)PubMedCrossRef Boulenger, S., Nixon, J., Drummond, M.F., Ulmann, P., Rice, S., de Pouvourville, G.: Can economic evaluations be made more transferable? Eur. J. Health Econ. 6, 334–346 (2005)PubMedCrossRef
3.
go back to reference Antonanzas, F., Rodriguez-Ibeas, R., Juarez, C., Hutter, F., Lorente, R., Pinillos, M.: Transferability indices for health economic evaluations: methods and applications. Health Econ. 18, 629–643 (2009)PubMedCrossRef Antonanzas, F., Rodriguez-Ibeas, R., Juarez, C., Hutter, F., Lorente, R., Pinillos, M.: Transferability indices for health economic evaluations: methods and applications. Health Econ. 18, 629–643 (2009)PubMedCrossRef
4.
go back to reference Nixon, J., Rice, S., Drummond, M., Boulenger, S., Ulmann, P., de Pouvourville, G.: Guidelines for completing the EURONHEED transferability information checklists. Eur. J. Health Econ. 10, 157–165 (2009)PubMedCrossRef Nixon, J., Rice, S., Drummond, M., Boulenger, S., Ulmann, P., de Pouvourville, G.: Guidelines for completing the EURONHEED transferability information checklists. Eur. J. Health Econ. 10, 157–165 (2009)PubMedCrossRef
5.
go back to reference Vemer, P., Rutten-van Mölken, M.P.M.H.: Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries. Value Health 13, 230–241 (2010)PubMedCrossRef Vemer, P., Rutten-van Mölken, M.P.M.H.: Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries. Value Health 13, 230–241 (2010)PubMedCrossRef
6.
go back to reference O’Regan C, Baker C, Marchant N. The cost-effectiveness of the novel prescription therapy varenicline in Scotland. In: Meeting of the Society for Research on Nicotine and Tobacco, 14–18 Feb, Madison (WI), USA (2006) O’Regan C, Baker C, Marchant N. The cost-effectiveness of the novel prescription therapy varenicline in Scotland. In: Meeting of the Society for Research on Nicotine and Tobacco, 14–18 Feb, Madison (WI), USA (2006)
7.
go back to reference Hoogendoorn, M., Welsing, P., Rutten-van Mölken, M.P.M.H.: Cost-effectiveness of varenicline compared with bupropion, NRT and nortriptyline for smoking cessation in the Netherlands. Curr. Med. Res. Op. 24, 51–61 (2008) Hoogendoorn, M., Welsing, P., Rutten-van Mölken, M.P.M.H.: Cost-effectiveness of varenicline compared with bupropion, NRT and nortriptyline for smoking cessation in the Netherlands. Curr. Med. Res. Op. 24, 51–61 (2008)
8.
go back to reference Bolin, K., Mörk, A., Willers, S., Lindgren, B.: Varenicline as compared to bupropion in smoking cessation therapy—Cost–utility results for Sweden. Respir. Med. 102, 699–710 (2008)PubMedCrossRef Bolin, K., Mörk, A., Willers, S., Lindgren, B.: Varenicline as compared to bupropion in smoking cessation therapy—Cost–utility results for Sweden. Respir. Med. 102, 699–710 (2008)PubMedCrossRef
9.
go back to reference Howard, P., Knight, C., Boler, A., Baker, C.: Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers. Pharmacoeconomics 26, 497–511 (2008)PubMedCrossRef Howard, P., Knight, C., Boler, A., Baker, C.: Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers. Pharmacoeconomics 26, 497–511 (2008)PubMedCrossRef
11.
go back to reference Jorenby, D.E., Hays, J.T., Rigotti, N.A., et al.: Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-released bupropion for smoking cessation: a randomized controlled trial. J. Am. Med. Assoc. 296, 56–63 (2006)CrossRef Jorenby, D.E., Hays, J.T., Rigotti, N.A., et al.: Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-released bupropion for smoking cessation: a randomized controlled trial. J. Am. Med. Assoc. 296, 56–63 (2006)CrossRef
12.
go back to reference Rasch, A., Greiner, W.: Gesundheitsökonomisches Modell der Raucherentwöhnung mit Vareniclin. Suchtmedizin in Forschung und Praxis 11, 47–55 (2009) Rasch, A., Greiner, W.: Gesundheitsökonomisches Modell der Raucherentwöhnung mit Vareniclin. Suchtmedizin in Forschung und Praxis 11, 47–55 (2009)
13.
go back to reference Annemans, L., Nackaerts, K., Bartsch, P., Prignot, J., Marbaix, S.: Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis. Clin. Drug Investig. 29, 655–665 (2009)PubMedCrossRef Annemans, L., Nackaerts, K., Bartsch, P., Prignot, J., Marbaix, S.: Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis. Clin. Drug Investig. 29, 655–665 (2009)PubMedCrossRef
14.
go back to reference Rawlins, M.D., Cuyler, A.J.: National Institute for Clinical Excellence and its value judgements. Br. Med. J. 329, 224–227 (2004)CrossRef Rawlins, M.D., Cuyler, A.J.: National Institute for Clinical Excellence and its value judgements. Br. Med. J. 329, 224–227 (2004)CrossRef
15.
go back to reference Pomp, M., Brouwer, W.B.F., Rutten, F.F.H.: QALY-tijd. Nieuwe medische technologie. kosteneffectiviteit en richtlijnen. Den Haag, Centraal Planbureau (CPB) (2007) Pomp, M., Brouwer, W.B.F., Rutten, F.F.H.: QALY-tijd. Nieuwe medische technologie. kosteneffectiviteit en richtlijnen. Den Haag, Centraal Planbureau (CPB) (2007)
16.
go back to reference RVZ. Zinnige en duurzame zorg (Sensible and sustainable Care). Zoetermeer. Raad voor de Volksgezondheid en Zorg (Council for Public Health and Health Care) Report nr. 06/06 (2006) RVZ. Zinnige en duurzame zorg (Sensible and sustainable Care). Zoetermeer. Raad voor de Volksgezondheid en Zorg (Council for Public Health and Health Care) Report nr. 06/06 (2006)
17.
go back to reference RVZ. Rechtvaardige en duurzame zorg (Justified and sustainable care). Den Haag. Raad voor de Volksgezondheid en Zorg (Council for Public Health and Health Care) Report nr. 07/04. ISBN 978-90-5732-183-2 (2007) RVZ. Rechtvaardige en duurzame zorg (Justified and sustainable care). Den Haag. Raad voor de Volksgezondheid en Zorg (Council for Public Health and Health Care) Report nr. 07/04. ISBN 978-90-5732-183-2 (2007)
18.
go back to reference Perleth, M., Gibis, B., Gohlen, B.: A short history of health technology assessment in Germany. Int. J. Technol. Assess. Health Care. 25(Suppl 1), 112–119 (2009)PubMedCrossRef Perleth, M., Gibis, B., Gohlen, B.: A short history of health technology assessment in Germany. Int. J. Technol. Assess. Health Care. 25(Suppl 1), 112–119 (2009)PubMedCrossRef
19.
go back to reference Cleemput, I., Van Wilder, P.: History of health technology assessment in Belgium. Int. J. Technol. Assess. Health Care. 25(Suppl 1), 82–87 (2009)PubMedCrossRef Cleemput, I., Van Wilder, P.: History of health technology assessment in Belgium. Int. J. Technol. Assess. Health Care. 25(Suppl 1), 82–87 (2009)PubMedCrossRef
20.
go back to reference KCE. Drempelwaarden voor kosteneffectiviteit in de gezondheidszorg. Brussels. Federaal Kenniscentrum voor de Gezondheidszorg (KCE). Report nr. 100A (2008) KCE. Drempelwaarden voor kosteneffectiviteit in de gezondheidszorg. Brussels. Federaal Kenniscentrum voor de Gezondheidszorg (KCE). Report nr. 100A (2008)
21.
go back to reference LFN. The Swedish pharmaceutical reimbursement system. Pharmaceutical Benefits Board (LFN), Solna (2007) LFN. The Swedish pharmaceutical reimbursement system. Pharmaceutical Benefits Board (LFN), Solna (2007)
22.
go back to reference Moïse P, Docteur E. Pharmaceutical pricing and reimbursement in Sweden. OECD health working papers no 28, OECD, Paris (2007) Moïse P, Docteur E. Pharmaceutical pricing and reimbursement in Sweden. OECD health working papers no 28, OECD, Paris (2007)
23.
go back to reference Rochaix L. In France, no threshold value is used when making health care decision. Report nr. 29006531, personal communication, 5 Jan (2010) Rochaix L. In France, no threshold value is used when making health care decision. Report nr. 29006531, personal communication, 5 Jan (2010)
24.
go back to reference Kroes ME, Mastenbroek CG. Stoppen-met-rokenprogramma: te verzekeren zorg! Diemen. CVZ (2009) Kroes ME, Mastenbroek CG. Stoppen-met-rokenprogramma: te verzekeren zorg! Diemen. CVZ (2009)
25.
go back to reference Thun, M.J., Apicella, L.F., Henley, S.J.: Smoking vs. other risk factors as the cause of smoking-attributable deaths: confounding in the courtroom. J. Am. Med. Assoc. 284, 706–712 (2000)CrossRef Thun, M.J., Apicella, L.F., Henley, S.J.: Smoking vs. other risk factors as the cause of smoking-attributable deaths: confounding in the courtroom. J. Am. Med. Assoc. 284, 706–712 (2000)CrossRef
26.
go back to reference Feenstra, T.L., van Genugten, M.L., Hoogenveen, R.T., Wouters, E.F., Rutten-van Mölken, M.P.M.H.: The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am. J. Respir. Crit. Care Med. 164, 590–596 (2001)PubMed Feenstra, T.L., van Genugten, M.L., Hoogenveen, R.T., Wouters, E.F., Rutten-van Mölken, M.P.M.H.: The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am. J. Respir. Crit. Care Med. 164, 590–596 (2001)PubMed
Metadata
Title
Largely ignored: the impact of the threshold value for a QALY on the importance of a transferability factor
Authors
Pepijn Vemer
Maureen P. M. H. Rutten-van Mölken
Publication date
01-10-2011
Publisher
Springer-Verlag
Published in
The European Journal of Health Economics / Issue 5/2011
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-010-0253-3

Other articles of this Issue 5/2011

The European Journal of Health Economics 5/2011 Go to the issue